0001209191-19-060476.txt : 20191213 0001209191-19-060476.hdr.sgml : 20191213 20191213173550 ACCESSION NUMBER: 0001209191-19-060476 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191212 FILED AS OF DATE: 20191213 DATE AS OF CHANGE: 20191213 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: YANG MICHAEL J. CENTRAL INDEX KEY: 0001702283 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-50768 FILM NUMBER: 191285397 MAIL ADDRESS: STREET 1: C/O ACADIA PHARMACEUTICALS INC. STREET 2: 3611 VALLEY CENTRE DRIVE,SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ACADIA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001070494 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 061376651 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3611 VALLEY CENTRE DRIVE STREET 2: SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: 858-558-2871 MAIL ADDRESS: STREET 1: 3611 VALLEY CENTRE DRIVE STREET 2: SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-12-12 0 0001070494 ACADIA PHARMACEUTICALS INC ACAD 0001702283 YANG MICHAEL J. C/O ACADIA PHARMACEUTICALS INC. 3611 VALLEY CENTRE DRIVE, STE. 300 SAN DIEGO CA 92130 0 1 0 0 EVP and CCO Common Stock 2019-12-12 4 M 0 22500 19.98 A 24999 D Common Stock 2019-12-12 4 M 0 10000 21.28 A 34999 D Common Stock 2019-12-12 4 M 0 72979 35.86 A 107978 D Common Stock 2019-12-12 4 S 0 100447 44.493 D 7531 D Common Stock 2019-12-12 4 S 0 5032 43.735 D 2499 D Stock Option (Right to Buy) 19.98 2019-12-12 4 M 0 22500 0.00 D 2028-04-17 Common Stock 22500 577500 D Stock Option (Right to Buy) 21.28 2019-12-12 4 M 0 10000 0.00 D 2028-10-14 Common Stock 10000 30000 D Stock Option (Right to Buy) 35.86 2019-12-12 4 M 0 72979 0.00 D 2027-03-28 Common Stock 72979 312500 D Includes 876 shares of the Issuer's common stock acquired by the reporting person on November 15, 2017 pursuant to an employee stock purchase program. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 6, 2019. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.755 to $44.75, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.67 to $43.75, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. 25% of the 600,000 shares originally subject to the Stock Option vested and became exercisable on April 18, 2019. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments 25% of the 40,000 shares originally subject to the Stock Option vested and became exercisable on October 15, 2019. The remaining shares vest and become excercisable thereafter in 36 equal monthly installments. 25% of the 400,000 shares originally subject to the stock option vested and became exercisable on March 29, 2018. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments. /s/ Austin D. Kim, Attorney-in-Fact 2019-12-13